更昔洛韦联合卡介菌多糖核酸治疗带状疱疹疗效观察

目的 探讨更昔洛韦联合卡介菌多糖核酸治疗带状疱疹的临床疗效.方法 将86例带状疱疹患者按随机数字表法分为观察组和对照组,每组43例.对照组单纯应用更昔洛韦治疗;观察组在此基础上联合应用卡介菌多糖核酸治疗,观察并比较两组疗效、修复皮肤损害(止疱、结痂)时间和疼痛缓解时间、后遗神经痛发生率和不良反应情况.结果 两组患者均顺利完成治疗,没有因为无法耐受药物而退出者.观察组止疱、结痂和疼痛缓解时间均较对照组明显缩短,差异有统计学意义(P＜0.05);后遗神经痛发生率明显低于对照组,差异有统计学意义(P＜0.05);治疗14 d后观察组有效率为90.7%(39/43),与对照组的74.4%(32/43)比较差异有统计学意义(P＜0.05);两组均无严重不良反应发生.结论 更昔洛韦联合卡介菌多糖核酸治疗带状疱疹疗效确切,安全可行.

Efficacy of ganciclovir combined with Bacillus Calmette-Guerin polysaccharide nucleic acid for the treatment of herpes zoster

Objective To investigate the clinical efficacy of ganciclovir combined with Bacillus Calmette-Guerin polysaccharide nucleic acid (BCG-PSN) for the treatment of herpes zoster. Methods Eighty-six cases with herpes zoster were randomly divided into study group and control group, 43 cases in each group. Patients of control group received simple ganciclovir treatment; while patients of the study group received BCG-PSN on this basis, then to observe and compare the efficacy, the repair time of skin lesions (herpes stopping, surface deposition), odynolysis time, remained neuralgia incidence and adverse reactions of two groups. Results Patients of two groups all completed the experiment successfully, no one withdraw from this trial because of no tolerance of drugs. The herpes stopping and surface deposition time and odynolysis time of study group were significantly shorter than those of control group, the difference was statistically significant (P＜0.05 ); the remained neuralgia incidence was significantly lower than that of control group,the difference was statistically significant (P＜0.05); the effective rate of study group in 14 days after treatment was 90.7% (39/43) and significantly higher than that of control group 74.4% (32/43)], the difference was statistically significant (P ＜ 0.05);there were no serious adverse reactions occurred in two groups. Conclusion Application of ganciclovir combined with BCG-PSN for the treatment of herpes zoster has certain efficacy, it is feasible and safe.